blood pressure reduction in context of cardiovasc risk assessment

Recent Lancet meta-analysis looking at the benefits of blood pressure lowering and relating that to overall cardiovascular risk (see htn blood pressure reduction cardiovasc risk lancet 2014 in dropbox, or Lancet 2014; 384: 591–98​). Findings:

--11 trials with 67,475 individuals, with  52K having data for overall cardiovasc risk assessment. 4167 (8%) had cardiovasc event over mean of 4 years. the data incorporated into their risk model included age, sex, BMI, syst and diast bp, antihypertensive meds, smoking, diabetes, hx of cardiovasc disease. did not have enough data about lipids. baseline 45% female, ave age 65, 15% smokers, 39% diabetic, BMI 27.8, BP 158/92.
--likelihood of cardiovasc event tracked with overall 5-yr cardiovasc risk. relative risk reduction (RRR) were and absolute risk reduction (ARR) for 1000 pts treated for hypertension for 5 years would be:
                --cardiovasc risk 6%: RRR 18% and ARR of 14 cardiovasc events/1000 pts treated
                --cardiovasc risk 12.1%: RRR 15% and ARR of 20 cardiovasc events/1000 pts treated
                --cardiovasc risk 17.7%: RRR 13% and ARR of 24 cardiovasc events/1000 pts treated
                --cardiovasc risk 26.8%: RRR 15% and ARR of 38 cardiovasc events/1000 pts
--non-significant difference in RRR according to cardiovasc risk, but ARR did have significant trend (p=.04)

so, this study reinforces the observation of the Framingham Study from a few decades ago: the attributable risk of any risk factor (including systolic blood pressure) is significantly higher if other risk factors are present (eg, the component of cardiovasc risk attributable to hypertension is markedly higher if the patient also has hyperlipidemia). probably the most important lesson of this study is that we should be looking at the whole picture, not just blood pressure in isolation. similar to what we do with lipids with the risk models. which means: in a person with lower levels of hypertension and no other risk factors, we can take a lower key approach, reinforcing lifestyle changes (weight, diet, exercise) for a longer period of time before starting meds. and vice versa.

Comments

Post a Comment

if you would like to receive the near-daily emails regularly, please email me at gmodest@uphams.org

Popular posts from this blog

HDL a negative risk factor? or cholesterol efflux??

Although the data on HDL being protective of atherosclerotic disease is pretty consistent, there are negative studies, and the data on medications which dramatically improve HDL levels (eg, the cholesteryl ester transfer protein --CETP --inhibitors, such as torcetrapib) are clinically disappointing. there have been several explanations for this. for example, some HDL particles are "pro-inflammatory" and elicit an atherosclerotic response (which may be related to apolipoprotein C-III). a new article in NEJM highlights another angle -- that the issue is not the HDL number, but HDL's functionality in the reverse transport of cholesterol, as measured by the cholesterol efflux capacity (see  lipids HDL efflux capacity vs amt NEJM 2014 in dropbox, or  DOI: 10.1056/NEJMoa1409065). This article looks at the Dallas Heart Study, where they measured HDL levels, HDL particle concentrations, and cholesterol efflux capacity in 2924 adults free of cardiovascular disease and followed p
Read more

Drug company shenanigans: narcolepsy drug

I have not done a blog for a long time on drug company shenanigans. So it is my great pleasure to bring up a brand-new drug company approach to garner huge amounts of money (see  https://www.nytimes.com/2023/02/28/business/jazz-narcolepsy-avadel-patents.html?smid=nytcore-ios-share&referringSource=articleShare  ).  Based on an article by  Rebecca Robbins of the New York Times, who has written several articles on drug company excesses   As background, this will be my 42 nd  such blog: for the array, see  https://bucommunitymed.wpengine.com/page/4/?s=drug+company+shenanigans   Th e drug company  approach  this time  to extending  their  patents has a few “interesting” angles: -- this is a medication manufactured by Jazz Pharmaceuticals to treat narcolepsy: there are 2 versions: Xyrem and Xywav (Xywav has less sodium, so is marketed to those who should be on a low sodium diet). These meds are basically derivatives of gammahydroxybutyric acid (GHB)      -- the drug actually has a pretty
Read more

UPDATE: ASCVD risk factor critique

  I decided to do an extensive update of my prior ASCVD (atherosclerotic cardiovascular disease) risk analysis and critique of risk calculators, with much more information about the “non-traditional” risk factors. I felt that there should be more data/clarification, since I think we are really undertreating/not preventing the most common cause of death by relying on the ASCVD risk calculators   -- Cardiovascular risk models:      -- many of us rely on the various cardiovascular risk models to determine the appropriate approach to patients, and these are often integrated into the electronic medical records      -- these risk models have several very important limitations:          -- they are typically based on community data, eg from the Framingham study etc. But, in clinical practice, we are dealing with the individual and not the community:              -- there is very clear evidence that there are many individual risk factors that are associated with increased risk of a cardiovascu
Read more